glofitamab
roche
['lymsm', 'glofitamab', 'lymphoma']
#eha2022 | duration of response with glofitamab was led by complete responses. of note, patients were off therapy at 9 months. in the prior ph i, durable responses were seen beyond 24 months #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm